List of Excipients in Branded Drug LAMOTRIGINE ER

Generic Drugs Containing LAMOTRIGINE ER

Company	Ingredient	NDC	Excipient
Direct_Rx	lamotrigine er	72189-467	FD&C BLUE NO. 2
Direct_Rx	lamotrigine er	72189-467	FERROSOFERRIC OXIDE
Direct_Rx	lamotrigine er	72189-467	GLYCERYL MONOSTEARATE
Direct_Rx	lamotrigine er	72189-467	HYPROMELLOSES

What are the Most Frequently-Used Excipients in LAMOTRIGINE ER?

# Of NDCs	Excipient
2	FD&C BLUE NO. 2
2	FERROSOFERRIC OXIDE
1	GLYCERYL MONO AND DIPALMITOSTEARATE
1	GLYCERYL MONOSTEARATE

Lamotrigine ER Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Lamotrigine extended-release (ER) is a mature oral solid-dose market with limited active-ingredient exclusivity and meaningful formulation barriers. Commercial opportunity depends on achieving reliable 24-hour release, avoiding dose-dumping, controlling food and alcohol effects, and reducing manufacturing cost without changing clinical performance. The strongest opportunities are generic ER supply, differentiated excipient platforms, patient-friendly dosage forms, and contract development and manufacturing services.

What is the commercial status of lamotrigine ER?

Lamotrigine ER is an extended-release tablet containing lamotrigine, an antiepileptic drug used primarily for partial-onset seizures. The reference product, Lamictal XR, was developed by GlaxoSmithKline and approved by the U.S. Food and Drug Administration in 2008.[1]

The product is available in multiple strengths, generally ranging from 25 mg to 300 mg. Its formulation is designed for once-daily administration, in contrast with immediate-release lamotrigine products that commonly require twice-daily dosing.

Commercial factor	Lamotrigine ER position
Active ingredient	Lamotrigine
Dosage form	Extended-release tablet
Reference product	Lamictal XR
Originator	GlaxoSmithKline
FDA approval	2008
Main indication	Partial-onset seizures
Primary regulatory pathway for competitors	ANDA
Biologic risk	None
Main technical barrier	Reproducible extended release and bioequivalence
Main commercial risk	Low-cost generic competition
Main differentiation routes	Release profile, tolerability, manufacturability, packaging, supply reliability

Lamotrigine is also marketed in immediate-release tablets, chewable tablets, orally disintegrating tablets and dispersible formulations. This creates substitution pressure but also leaves an opportunity for a reliable once-daily ER product targeted at adherence-sensitive patients.

What excipients are used in lamotrigine ER tablets?

Public labels identify the inactive ingredients in approved products, but they do not disclose the complete manufacturing process or quantitative composition. Reference and generic products may use different excipients while meeting the same release and bioequivalence requirements.

Typical excipient functions include:

Excipient function	Candidate materials	Role in lamotrigine ER
Release-controlling polymer	Hypromellose, ethylcellulose, methacrylate copolymers	Controls hydration, diffusion and erosion
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Provides tablet mass and compression properties
Binder	Povidone, copovidone, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Crospovidone, croscarmellose sodium, sodium starch glycolate	May be used in non-release-controlling portions
Lubricant	Magnesium stearate, sodium stearyl fumarate	Reduces sticking and ejection force
Glidant	Colloidal silicon dioxide, talc	Improves powder flow
Film former	Hypromellose, polyvinyl alcohol	Protects the tablet and supports appearance
Plasticizer	Polyethylene glycol, triacetin	Improves coating flexibility
Colorant or opacifier	Titanium dioxide, iron oxides, approved lakes	Supports strength identification and product appearance

The key formulation decision is whether the ER matrix should control release through polymer swelling, polymer erosion, diffusion, multiparticulate coating, or a combination of these mechanisms.

Public product information for Lamictal XR identifies conventional pharmaceutical excipients, including matrix or coating materials, fillers, lubricants and coloring agents. Generic labels should be reviewed individually because inactive ingredients, color systems and tablet-coating compositions vary by manufacturer.[2]

Which excipient platforms are best suited to lamotrigine ER?

Hydrophilic matrix tablets

Hydrophilic matrices based on hypromellose are the most accessible development platform. After ingestion, the polymer hydrates and forms a gel layer. Lamotrigine diffuses through the hydrated matrix while erosion contributes to later-stage release.

Advantages include:

• Established regulatory history.
• Low manufacturing complexity.
• Compatibility with direct compression or wet granulation.
• Ability to adjust release by changing polymer viscosity and loading.
• Suitability for multiple strengths.

The principal risks are sensitivity to tablet hardness, polymer grade, drug loading, dissolution medium and gastrointestinal hydrodynamics. A formulation that performs acceptably in a standard dissolution test may still show clinically relevant variability under high agitation or altered food conditions.

Hydrophobic matrix systems

Ethylcellulose, waxes and lipid-based excipients can reduce water penetration and create a slower release profile. These systems may be useful when a hydrophilic matrix releases lamotrigine too rapidly or shows excessive sensitivity to agitation.

The tradeoffs include more complex scale-up, greater sensitivity to granulation and milling, and potential difficulty maintaining dose proportionality across strengths.

Polymer-coated multiparticulates

Lamotrigine can be incorporated into coated pellets or granules, which are then filled into capsules or compressed into tablets. Coating thickness, polymer permeability and pellet size determine release.

This platform can provide better control of dose dumping and may support sprinkle or swallow-friendly products. Its disadvantages are higher manufacturing cost, more process variables and a larger analytical burden.

Osmotic or membrane-controlled systems

Osmotic delivery can provide a more predictable release profile but is usually less attractive for a generic lamotrigine ER product because of tooling, membrane-coating and process-control costs. The technology may have value for a premium product only if it delivers a clear clinical or adherence benefit.

What formulation attributes determine commercial success?

The most important quality target is a robust dissolution profile across physiological and manufacturing conditions.

Release-profile control

Development should evaluate:

• Multiple pH conditions.
• Low and high agitation.
• Fed and fasted media.
• Alcohol-containing media.
• Tablet hardness and porosity.
• Storage-related changes.
• Mechanical stress during packaging and shipping.
• Variability between dose strengths.

Alcohol-induced dose dumping is a key concern for modified-release oral products. A formulation that accelerates release in the presence of alcohol can create regulatory and liability exposure. Alcohol challenge testing should be integrated into formulation selection rather than treated as a late-stage exercise.

Dose proportionality

Lamotrigine ER products may use different tablet compositions at different strengths. A scalable strategy should determine whether one matrix can be used across strengths or whether polymer content must change with drug loading.

A common commercial objective is proportional composition across strengths. This reduces manufacturing complexity, simplifies validation and may lower inventory requirements. The approach is not always technically feasible because low-dose tablets can have different surface-area-to-volume ratios and different release kinetics.

Tablet size and swallowability

Lamotrigine doses can be high relative to many orally active drugs. Excessive tablet size can reduce adherence, particularly in epilepsy patients who already take multiple medicines.

Excipient selection should therefore balance:

• Drug loading.
• Compressibility.
• Tablet volume.
• Mechanical strength.
• Coating weight.
• Dose uniformity.
• Ease of swallowing.

High-functionality excipients, co-processed fillers and optimized granulation may create commercial value if they reduce tablet size without compromising release.

Stability

Lamotrigine ER products should be evaluated for:

• Moisture uptake.
• Polymer aging.
• Changes in tablet hardness.
• Dissolution drift.
• Degradation products.
• Color migration.
• Packaging compatibility.

A moisture-barrier blister or high-barrier bottle may permit a simpler formulation. Conversely, a low-cost bottle may require desiccant protection or a more stable coating system.

What patents protect lamotrigine ER formulations?

The active-ingredient patent estate for lamotrigine is mature, and the principal commercial barriers are no longer expected to arise from basic composition-of-matter protection. The relevant IP categories are formulation, release-control technology, dosage regimen, manufacturing process and polymorph or solid-state claims.

IP category	Relevance to lamotrigine ER	Commercial impact
Composition of matter	Largely expired for the original molecule	Low barrier to generic entry
Extended-release formulation	May cover polymer systems, release profiles or dosage forms	Can delay or complicate entry
Method of treatment	May cover once-daily use or seizure-treatment regimens	Often narrower enforcement value
Manufacturing process	May cover granulation, coating or compression steps	Can require process redesign
Solid-state claims	Potentially relevant to crystalline forms or particle properties	Usually secondary to formulation claims
Device or packaging	Limited role for conventional tablets	Can protect differentiated delivery formats

U.S. formulation patents must be reviewed through the FDA Orange Book, USPTO records and litigation databases. Orange Book listing is important because a listed patent can support a Paragraph IV certification and patent litigation under the Hatch-Waxman framework.[3]

Because lamotrigine ER is a small-molecule product, biosimilar risk does not apply. Competitors file ANDAs, not biosimilar applications. FDA approval depends on pharmaceutical equivalence, bioequivalence, manufacturing quality and labeling conformity.

When does lamotrigine ER lose exclusivity?

Lamictal XR’s regulatory exclusivity and core patent protection are mature. The exact entry position for any competitor depends on the Orange Book record at the time of filing, listed patents, pediatric exclusivity, certification strategy and litigation outcomes.

The main milestones are:

Milestone	Commercial significance
2008 FDA approval of Lamictal XR	Established the reference ER product
Patent and regulatory exclusivity period	Protected early U.S. commercial position
ANDA eligibility	Enabled generic ER development
Paragraph IV certification	Can trigger patent litigation and a 30-month stay
Final FDA approval	Permits commercial launch subject to patent risk
Multiple generic approvals	Compresses price and margin

A generic applicant may file a Paragraph IV certification when it asserts that a listed patent is invalid, unenforceable or will not be infringed. The reference sponsor may then file suit within the statutory period, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework.[4]

What is the Orange Book status of lamotrigine ER?

The Orange Book should be used to confirm the current reference listed drug, therapeutic equivalence codes and any active patents listed against Lamictal XR. The status can change through patent delisting, expiration, correction or product discontinuation.

For commercial diligence, the following records should be reconciled:

1. FDA Orange Book patent listings.
2. FDA approval letters.
3. Current Lamictal XR labeling.
4. Approved generic labels.
5. USPTO patent prosecution records.
6. Federal court docket activity.
7. FDA drug shortages and discontinuation records.

Patent expiry dates should not be inferred solely from the original filing date. Patent term adjustment, patent term extension, terminal disclaimers and pediatric exclusivity can alter the effective protection period.

What generic entry risks exist for lamotrigine ER?

The primary generic risks are price erosion, supply concentration and substitution toward immediate-release products.

Price erosion

Lamotrigine ER is vulnerable to rapid price compression once several ANDA holders enter. The formulation is technically more difficult than immediate-release tablets, but the market remains a conventional oral solid-dose category with limited barriers after successful bioequivalence approval.

Limited differentiation

Most generic companies will compete on:

• Wholesale acquisition cost.
• Contract coverage.
• Manufacturing reliability.
• Number of approved strengths.
• Pharmacy substitution.
• Shortage avoidance.

A generic product with no meaningful formulation or supply advantage may have limited margin after launch.

Bioequivalence failure

ER products can fail development because of:

• Inadequate fed-state performance.
• Excessive variability in partial area under the curve.
• Dose dumping under alcohol challenge.
• Strength-specific dissolution differences.
• Failure to match the reference product’s absorption profile.
• Unacceptable food effect.

These risks favor companies with established modified-release development platforms.

Supply-chain risk

Lamotrigine requires dependable API sourcing, validated excipient supply and tight control of polymer grades. Changes in hypromellose viscosity, lactose particle size, magnesium stearate surface area or coating materials can affect dissolution.

A dual-source strategy for critical excipients may have greater commercial value than a marginal reduction in material cost.

What commercial opportunities exist for lamotrigine ER excipients?

Excipient suppliers

The strongest supplier opportunity is a validated modified-release excipient system that reduces development time. Value increases when the supplier provides:

• Multiple viscosity grades.
• Compression data.
• Dissolution benchmarking.
• Scale-up guidance.
• Regulatory support.
• Global supply qualification.
• Functionality testing after storage.

A co-processed excipient designed for direct compression could reduce granulation steps and improve manufacturing consistency.

Generic manufacturers

Generic companies can pursue a low-cost matrix platform with common composition across strengths. The commercial target is not merely FDA approval. It is a product with low batch variability, low tablet weight and stable dissolution after long-term storage.

Specialty manufacturers

A manufacturer may pursue a smaller commercial segment with:

• Sprinkle-capable capsules.
• Smaller tablets.
• Packaging designed for adherence.
• Products for patients with swallowing difficulty.
• Consistent supply during generic shortages.
• Regional licensing rights.

Any new dosage form must be evaluated against FDA requirements for bioequivalence, labeling and clinical usability.

Licensing opportunities

Potential licensing structures include:

Asset	Likely transaction model
ER formulation platform	Upfront payment plus milestones and royalties
Approved ANDA	Product acquisition or regional commercialization
Ready-to-file formulation	Development partnership
Excipient technology	Nonexclusive formulation license
Manufacturing process	Technology transfer and supply agreement
Regional product rights	Territory-based royalty arrangement

The most defensible licensing asset is an approved or near-approval product with a clear cost advantage, complete strength portfolio and documented dissolution robustness.

How does lamotrigine ER compare with other modified-release antiepileptics?

Product category	Main advantage	Main barrier	Commercial implication
Lamotrigine ER	Once-daily dosing and established molecule	Modified-release bioequivalence	Generic competition with formulation risk
Levetiracetam ER	Broad use and simple oral solid-dose demand	High generic competition	Larger volume, lower differentiation
Divalproex ER	Established ER use	Food, tolerability and formulation complexity	Mature but broad market
Carbamazepine ER	Long clinical history	Narrow therapeutic considerations	Established controlled-release competition
Immediate-release lamotrigine	Lower manufacturing complexity	More frequent dosing	Price pressure on ER products

Lamotrigine ER has an adherence advantage over immediate-release lamotrigine but does not have the exclusivity profile of a newly launched therapy. Its commercial value is therefore linked to execution, not molecule novelty.

What manufacturing and IP barriers affect lamotrigine ER?

Manufacturing barriers are moderate. They are higher than for immediate-release lamotrigine but lower than for complex injectables, inhaled products or biologics.

Key barriers include:

• Consistent polymer distribution.
• Uniform granule density.
• Control of tablet porosity.
• Reproducible coating thickness.
• Dissolution matching across strengths.
• Process validation after scale-up.
• Excipient lot-to-lot consistency.
• Stability under commercial packaging.

The strongest process IP may relate to specific polymer ratios, granulation conditions, coating parameters or dissolution profiles. Broad claims are more vulnerable to prior art and design-around strategies. Narrow claims can be easier to defend but may provide limited exclusionary coverage.

What is the outlook for lamotrigine ER?

Lamotrigine ER is a defensible but mature formulation opportunity. The best commercial prospects are:

1. A low-cost, multi-strength generic platform.
2. A differentiated tablet with reduced size or improved swallowability.
3. A sprinkle or capsule-based product with a clear patient-use advantage.
4. A validated excipient package that accelerates ANDA development.
5. A reliable secondary-source product for wholesalers and health systems.
6. Regional licensing where generic supply is limited.
7. Manufacturing services for companies lacking modified-release capabilities.

The weakest opportunity is an undifferentiated tablet that competes only on price after multiple generic approvals.

Key Takeaways

• Lamotrigine ER is a mature small-molecule market with no biosimilar pathway.
• The principal technical challenge is matching the reference product’s release and absorption profile.
• Hypromellose-based hydrophilic matrices are the most practical starting platform.
• Alcohol dose-dumping, food effects, tablet size and strength-specific dissolution require early evaluation.
• Active-ingredient exclusivity is not the main barrier; formulation and process IP are more relevant.
• ANDA applicants should review Orange Book listings, Paragraph IV exposure and litigation history before launch.
• Commercial value is strongest in reliable multi-strength supply, lower manufacturing cost and patient-use differentiation.
• Excipient suppliers can create value through validated, regulatory-ready modified-release systems rather than commodity materials alone.

FAQs

Can lamotrigine ER be formulated with common excipients?

Yes. Conventional matrix polymers, fillers, binders and lubricants can support development, but the exact grade, particle size, viscosity and processing conditions can materially change dissolution.

Is hypromellose sufficient to create a commercially robust lamotrigine ER product?

Not necessarily. Hypromellose can provide the primary release-control mechanism, but the final product requires optimization of drug loading, tablet hardness, polymer level, excipient distribution and coating.

Does lamotrigine ER have biosimilar competition?

No. Lamotrigine is a chemically synthesized small molecule. Competitors use the ANDA generic pathway rather than the biosimilar pathway.

Can an excipient supplier patent a lamotrigine ER formulation?

Yes. Patent protection may be available for defined excipient combinations, polymer ratios, release profiles, manufacturing processes or dosage forms, subject to novelty, nonobviousness, written-description and enablement requirements.

What is the most attractive differentiated product concept?

A small, once-daily dosage form with robust dissolution, low food and alcohol sensitivity, complete strength coverage and dependable supply has the clearest commercial rationale.

References

1. U.S. Food and Drug Administration. (2008). Lamictal XR approval letter and prescribing information. FDA.

2. DailyMed. (n.d.). Lamictal XR: Lamotrigine extended-release tablets prescribing information. National Library of Medicine.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application process under the Hatch-Waxman Amendments. FDA.

5. U.S. Food and Drug Administration. (2017). Guidance for industry: Extended release oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations. FDA.

6. U.S. Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.